Immune Regulation makes Peter Greenleaf chairman and assembles a quintet of new execs; Bob Coughlin moves on from MassBio to JLL
→ In September, Immune Regulation raked in $53.4 million in a Series B for two programs in rheumatoid arthritis and asthma. This week, the British biotech has named Aurinia CEO Peter Greenleaf chairman of the board while announcing five appointees that have joined CEO Jonathan Rigby’s crew. Greenleaf took the reins at Aurinia — which just yesterday struck up an agreement with Otsuka to commercialize voclosporin in Japan and Europe — in April 2019. He was also the CEO of Cerecor and Sucampo Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.